Potential prognostic and predictive value of UBE2N, IMPDH1, DYNC1LI1 and HRASLS2 in colorectal cancer stool specimens

Chen,Yu-Nung; Shih,Cheng-Yen; Guo,Shu-Lin; Liu,Chih-Yi; Shen,Ming-Hung; Chang,Shih-Chang; Ku,Wei-Chi; Huang,Chi-Cheng; Huang,Chi-Jung

doi:10.3892/br.2023.1604

Potential prognostic and predictive value of UBE2N, IMPDH1, DYNC1LI1 and HRASLS2 in colorectal cancer stool specimens

Authors:
- Yu-Nung Chen
- Cheng-Yen Shih
- Shu-Lin Guo
- Chih-Yi Liu
- Ming-Hung Shen
- Shih-Chang Chang
- Wei-Chi Ku
- Chi-Cheng Huang
- Chi-Jung Huang
View Affiliations

Affiliations: Division of Colorectal Surgery, Department of Surgery, Cathay General Hospital, Taipei 10630, Taiwan, R.O.C., Division of Gastroenterology, Department of Internal Medicine, Sijhih Cathay General Hospital, New Taipei 22174, Taiwan, R.O.C., School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei 24205, Taiwan, R.O.C., Comprehensive Breast Health Center, Department of Surgery, Taipei Veterans General Hospital, Taipei 11217, Taiwan, R.O.C., Department of Medical Research, Cathay General Hospital, Taipei 10630, Taiwan, R.O.C.
Published online on: February 7, 2023 https://doi.org/10.3892/br.2023.1604
Article Number: 22
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is the most common gastrointestinal malignancy worldwide. The poor specificity and sensitivity of the fecal occult blood test has prompted the development of CRC‑related genetic markers for CRC screening and treatment. Gene expression profiles in stool specimens are effective, sensitive and clinically applicable. Herein, a novel advantage of using cells shed from the colon is presented for cost‑effective CRC screening. Molecular panels were generated through a series of leave‑one‑out cross‑validation and discriminant analyses. A logistic regression model following reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and immunohistochemistry was used to validate a specific panel for CRC prediction. The panel, consisting of ubiquitin‑conjugating enzyme E2 N (UBE2N), inosine monophosphate dehydrogenase 1 (IMPDH1), dynein cytoplasmic 1 light intermediate chain 1 (DYNC1LI1) and phospholipase A and acyltransferase 2 (HRASLS2), accurately recognized patients with CRC and could thus be further investigated as a potential prognostic and predictive biomarker for CRC. UBE2N, IMPDH1 and DYNC1LI1 expression levels were upregulated and HRASLS2 expression was downregulated in CRC tissues. The predictive power of the panel was 96.6% [95% confidence interval (CI), 88.1‑99.6%] sensitivity and 89.7% (95% CI, 72.6‑97.8%) specificity at a predicted cut‑off value at 0.540, suggesting that this four‑gene panel testing of stool specimens can faithfully mirror the state of the colon. On the whole, the present study demonstrates that screening for CRC or cancer detection in stool specimens collected non‑invasively does not require the inclusion of an excessive number of genes, and colonic defects can be identified via the detection of an aberrant protein in the mucosa or submucosa.

View Figures

View References

1	Taniguchi H, Moriya C, Igarashi H, Saitoh A, Yamamoto H, Adachi Y and Imai K: Cancer stem cells in human gastrointestinal cancer. Cancer Sci. 107:1556–1562. 2016.PubMed/NCBI View Article : Google Scholar
2	Miyake M, Takemasa I, Matoba R, Tanino M, Niijima S, Ikeda M, Yamamoto H, Sekimoto M, Kuhara S, Okayama T, et al: Heterogeneity of colorectal cancers and extraction of discriminator gene signatures for personalized prediction of prognosis. Int J Oncol. 39:781–789. 2011.PubMed/NCBI View Article : Google Scholar
3	Pitroda SP and Weichselbaum RR: Integrated molecular and clinical staging defines the spectrum of metastatic cancer. Nat Rev Clin Oncol. 16:581–588. 2019.PubMed/NCBI View Article : Google Scholar
4	Wang S, Guan X, Ma M, Zhuang M, Ma T, Liu Z, Chen H, Jiang Z, Chen Y, Wang G and Wang X: Reconsidering the prognostic significance of tumour deposit count in the TNM staging system for colorectal cancer. Sci Rep. 10(89)2020.PubMed/NCBI View Article : Google Scholar
5	Das V, Kalita J and Pal M: Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges. Biomed Pharmacother. 87:8–19. 2017.PubMed/NCBI View Article : Google Scholar
6	Sudoyo AW: Biomolecular markers as determinants of patients selection for adjuvant chemotherapy of sporadic colorectal cancers. Acta Med Indones. 42:45–50. 2010.PubMed/NCBI
7	Dong L and Ren H: Blood-based DNA methylation biomarkers for early detection of colorectal cancer. J Proteomics Bioinform. 11(120)2018.PubMed/NCBI View Article : Google Scholar
8	Wilhelmsen M, Christensen IJ, Rasmussen L, Jørgensen LN, Madsen MR, Vilandt J, Hillig T, Klaerke M, Nielsen KT, Laurberg S, et al: Detection of colorectal neoplasia: Combination of eight blood-based, cancer-associated protein biomarkers. Int J Cancer. 140:1436–1446. 2017.PubMed/NCBI View Article : Google Scholar
9	Marshall KW, Mohr S, Khettabi FE, Nossova N, Chao S, Bao W, Ma J, Li XJ and Liew CC: A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer. 126:1177–1186. 2010.PubMed/NCBI View Article : Google Scholar
10	Rodriguez-Casanova A, Costa-Fraga N, Bao-Caamano A, López-López R, Muinelo-Romay L and Diaz-Lagares A: Epigenetic landscape of liquid biopsy in colorectal cancer. Front Cell Dev Biol. 9(622459)2021.PubMed/NCBI View Article : Google Scholar
11	Xu Y, Xu Q, Yang L, Ye X, Liu F, Wu F, Ni S, Tan C, Cai G, Meng X, et al: Identification and validation of a blood-based 18-gene expression signature in colorectal cancer. Clin Cancer Res. 19:3039–3049. 2013.PubMed/NCBI View Article : Google Scholar
12	Huang CC, Shen MH, Chen SK, Yang SH, Liu CY, Guo JW, Chang KW and Huang CJ: Gut butyrate-producing organisms correlate to Placenta specific 8 protein: Importance to colorectal cancer progression. J Adv Res. 22:7–20. 2020.PubMed/NCBI View Article : Google Scholar
13	Huang CJ, Lee CL, Yang SH, Chien CC, Huang CC, Yang RN and Chang CC: Upregulation of the growth arrest-specific-2 in recurrent colorectal cancers, and its susceptibility to chemotherapy in a model cell system. Biochim Biophys Acta. 1862:1345–1353. 2016.PubMed/NCBI View Article : Google Scholar
14	Lee CL, Huang CJ, Yang SH, Chang CC, Huang CC, Chien CC and Yang RN: Discovery of genes from feces correlated with colorectal cancer progression. Oncol Lett. 12:3378–3384. 2016.PubMed/NCBI View Article : Google Scholar
15	Corbo C, Cevenini A and Salvatore F: Biomarker discovery by proteomics-based approaches for early detection and personalized medicine in colorectal cancer. Proteomics Clin Appl. 11(1600072)2017.PubMed/NCBI View Article : Google Scholar
16	Imperiale TF, Kisiel JB, Itzkowitz SH, Scheu B, Duimstra EK, Statz S, Berger BM and Limburg PJ: Specificity of the multi-target stool DNA test for colorectal cancer screening in average-risk 45-49 year-olds: A cross-sectional study. Cancer Prev Res (Phila). 14:489–496. 2021.PubMed/NCBI View Article : Google Scholar
17	Lin J, Zhang L, Chen M, Chen J, Wu Y, Wang T, Lu Y, Ba Z, Cheng X, Xu R, et al: Evaluation of combined detection of multigene mutation and SDC2/SFRP2 methylation in stool specimens for colorectal cancer early diagnosis. Int J Colorectal Dis. 37:1231–1238. 2022.PubMed/NCBI View Article : Google Scholar
18	Vega-Benedetti AF, Loi E, Moi L, Orrù S, Ziranu P, Pretta A, Lai E, Puzzoni M, Ciccone L, Casadei-Gardini A, et al: Colorectal cancer early detection in stool samples tracing CpG islands methylation alterations affecting gene expression. Int J Mol Sci. 21(4494)2020.PubMed/NCBI View Article : Google Scholar
19	Chen J, Sun H, Tang W, Zhou L, Xie X, Qu Z, Chen M, Wang S, Yang T, Dai Y, et al: DNA methylation biomarkers in stool for early screening of colorectal cancer. J Cancer. 10:5264–5271. 2019.PubMed/NCBI View Article : Google Scholar
20	De Wijkerslooth T, Bossuyt P and Dekker E: Strategies in screening for colon carcinoma. Neth J Med. 69:112–119. 2011.PubMed/NCBI
21	Young GP and Bosch LJW: Fecal tests: From blood to molecular markers. Curr Colorectal Cancer Rep. 7:62–70. 2011.PubMed/NCBI View Article : Google Scholar
22	Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, Taylor WR, Butz ML, Thibodeau SN, Rabeneck L, Paszat LF, et al: Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 142:248–256.e25-e26. 2012.PubMed/NCBI View Article : Google Scholar
23	Miller S and Steele S: Novel molecular screening approaches in colorectal cancer. J Surg Oncol. 105:459–467. 2012.PubMed/NCBI View Article : Google Scholar
24	Pox C: Colon cancer screening: Which non-invasive filter tests? Dig Dis. 29:56–59. 2011.PubMed/NCBI View Article : Google Scholar
25	Komor MA, Bosch LJ, Coupé VM, Rausch C, Pham TV, Piersma SR, Mongera S, Mulder CJ, Dekker E, Kuipers EJ, et al: Proteins in stool as biomarkers for non-invasive detection of colorectal adenomas with high risk of progression. J Pathol. 250:288–298. 2020.PubMed/NCBI View Article : Google Scholar
26	Choi HH, Cho YS, Choi JH, Kim HK, Kim SS and Chae HS: Stool-based miR-92a and miR-144* as noninvasive biomarkers for colorectal cancer screening. Oncology. 97:173–179. 2019.PubMed/NCBI View Article : Google Scholar
27	Steele RJ, Kostourou I, McClements P, Watling C, Libby G, Weller D, Brewster DH, Black R, Carey FA and Fraser C: Effect of repeated invitations on uptake of colorectal cancer screening using faecal occult blood testing: Analysis of prevalence and incidence screening. BMJ. 341(c5531)2010.PubMed/NCBI View Article : Google Scholar
28	Tonus C, Sellinger M, Koss K and Neupert G: Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: A meta-analysis. World J Gastroenterol. 18:4004–4011. 2012.PubMed/NCBI View Article : Google Scholar
29	Osborn NK and Ahlquist DA: Stool screening for colorectal cancer: Molecular approaches. Gastroenterology. 128:192–206. 2005.PubMed/NCBI View Article : Google Scholar
30	Hamaya Y, Yoshida K, Takai T, Ikuma M, Hishida A and Kanaoka S: Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer. Br J Cancer. 102:916–921. 2010.PubMed/NCBI View Article : Google Scholar
31	Mojtabanezhad Shariatpanahi A, Yassi M, Nouraie M, Sahebkar A, Varshoee Tabrizi F and Kerachian MA: The importance of stool DNA methylation in colorectal cancer diagnosis: A meta-analysis. PLoS One. 13(e0200735)2018.PubMed/NCBI View Article : Google Scholar
32	Robertson DJ and Imperiale TF: Stool testing for colorectal cancer screening. Gastroenterology. 149:1286–1293. 2015.PubMed/NCBI View Article : Google Scholar
33	Yang SH, Huang CJ, Lee CL, Liu CC, Chien CC and Chen SH: Fecal RNA detection of cytokeratin 19 and ribosomal protein L19 for colorectal cancer. Hepatogastroenterology. 57:710–715. 2010.PubMed/NCBI
34	Song L, Lu H and Yin J: Preliminary study on discriminating HER2 2+ amplification status of breast cancers based on texture features semi-automatically derived from pre-, post-contrast, and subtraction images of DCE-MRI. PLoS One. 15(e0234800)2020.PubMed/NCBI View Article : Google Scholar
35	Juhola M, Joutsijoki H, Penttinen K, Shah D and Aalto-Setälä K: On computational classification of genetic cardiac diseases applying iPSC cardiomyocytes. Comput Methods Programs Biomed. 210(106367)2021.PubMed/NCBI View Article : Google Scholar
36	Yu Z, Yu H, Zou Q, Huang Z, Wang X, Tang G, Bai L, Zhou C, Zhuang Z, Xie Y, et al: Nomograms for prediction of molecular phenotypes in colorectal cancer. Onco Targets Ther. 13:309–321. 2020.PubMed/NCBI View Article : Google Scholar
37	Liu CY, Huang CS, Huang CC, Ku WC, Shih HY and Huang CJ: Co-occurrence of differentiated thyroid cancer and second primary malignancy: Correlation with expression profiles of mismatch repair protein and cell cycle regulators. Cancers (Basel). 13(5486)2021.PubMed/NCBI View Article : Google Scholar
38	Weiser MR: AJCC 8th edition: Colorectal cancer. Ann Surg Oncol. 25:1454–1455. 2018.PubMed/NCBI View Article : Google Scholar
39	Treanor D and Quirke P: Pathology of colorectal cancer. Clin Oncol (R Coll Radiol). 19:769–776. 2007.PubMed/NCBI View Article : Google Scholar
40	Chien CC, Chang CC, Yang SH, Chen SH and Huang CJ: A homologue of the Drosophila headcase protein is a novel tumor marker for early-stage colorectal cancer. Oncol Rep. 15:919–926. 2006.PubMed/NCBI
41	Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, Crown J, Kiernan I, O'Byrne KJ, Kennedy MJ, Lynch V and Clynes M: Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer. 131:911–923. 2012.PubMed/NCBI View Article : Google Scholar
42	Ginestier C, Cervera N, Finetti P, Esteyries S, Esterni B, Adélaïde J, Xerri L, Viens P, Jacquemier J, Charafe-Jauffret E, et al: Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res. 12:4533–4544. 2006.PubMed/NCBI View Article : Google Scholar
43	Bair E and Tibshirani R: Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol. 2(E108)2004.PubMed/NCBI View Article : Google Scholar
44	Chou HL, Yao CT, Su SL, Lee CY, Hu KY, Terng HJ, Shih YW, Chang YT, Lu YF, Chang CW, et al: Gene expression profiling of breast cancer survivability by pooled cDNA microarray analysis using logistic regression, artificial neural networks and decision trees. BMC Bioinformatics. 14(100)2013.PubMed/NCBI View Article : Google Scholar
45	Hughes G: On the binormal predictive receiver operating characteristic curve for the joint assessment of positive and negative predictive values. Entropy (Basel). 22(593)2020.PubMed/NCBI View Article : Google Scholar
46	Yang SH, Chien CC, Chen CW, Li SY and Huang CJ: Potential of faecal RNA in diagnosing colorectal cancer. Cancer Lett. 226:55–63. 2005.PubMed/NCBI View Article : Google Scholar
47	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
48	Chang CC, Kao WY, Liu CY, Su HH, Kan YA, Lin PY, Ku WC, Chang KW, Yang RN and Huang CJ: Butyrate supplementation regulates expression of chromosome segregation 1-like protein to reverse the genetic distortion caused by p53 mutations in colorectal cancer. Int J Oncol. 60(64)2022.PubMed/NCBI View Article : Google Scholar
49	Wei Q, Jiang H, Baker A, Dodge LK, Gerard M, Young MR, Toledano MB and Colburn NH: Loss of sulfiredoxin renders mice resistant to azoxymethane/dextran sulfate sodium-induced colon carcinogenesis. Carcinogenesis. 34:1403–1410. 2013.PubMed/NCBI View Article : Google Scholar
50	Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, et al: QuPath: Open source software for digital pathology image analysis. Sci Rep. 7(16878)2017.PubMed/NCBI View Article : Google Scholar
51	Huang CJ, Chien CC, Yang SH, Chang CC, Sun HL, Cheng YC, Liu CC, Lin SC and Lin CM: Faecal ribosomal protein L19 is a genetic prognostic factor for survival in colorectal cancer. J Cell Mol Med. 12:1936–1943. 2008.PubMed/NCBI View Article : Google Scholar
52	Bernal G: Use of RNA isolated from feces as a promising tool for the early detection of colorectal cancer. Int J Biol Markers. 27:e82–e89. 2012.PubMed/NCBI View Article : Google Scholar
53	Grizzi F, Celesti G, Basso G and Laghi L: Tumor budding as a potential histopathological biomarker in colorectal cancer: Hype or hope? World J Gastroenterol. 18:6532–6536. 2012.PubMed/NCBI View Article : Google Scholar
54	Belletti B, Nicoloso MS, Schiappacassi M, Chimienti E, Berton S, Lovat F, Colombatti A and Baldassarre G: p27(kip1) functional regulation in human cancer: A potential target for therapeutic designs. Curr Med Chem. 12:1589–1605. 2005.PubMed/NCBI View Article : Google Scholar
55	Blázquez C, Geelen MJ, Velasco G and Guzmán M: The AMP-activated protein kinase prevents ceramide synthesis de novo and apoptosis in astrocytes. FEBS Lett. 489:149–153. 2001.PubMed/NCBI View Article : Google Scholar
56	Nikolouzakis TK, Vassilopoulou L, Fragkiadaki P, Mariolis Sapsakos T, Papadakis GZ, Spandidos DA, Tsatsakis AM and Tsiaoussis J: Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review). Oncol Rep. 39:2455–2472. 2018.PubMed/NCBI View Article : Google Scholar
57	Cheng YW and Li YC: Factors affecting the follow-up time after a positive result in the fecal occult blood test. PLoS One. 16(e0258130)2021.PubMed/NCBI View Article : Google Scholar
58	Bardhan K and Liu K: Epigenetics and colorectal cancer pathogenesis. Cancers (Basel). 5:676–713. 2013.PubMed/NCBI View Article : Google Scholar
59	Mundade R, Imperiale TF, Prabhu L, Loehrer PJ and Lu T: Genetic pathways, prevention, and treatment of sporadic colorectal cancer. Oncoscience. 1:400–406. 2014.PubMed/NCBI View Article : Google Scholar
60	Ahlquist DA: Molecular detection of colorectal neoplasia. Gastroenterology. 138:2127–2139. 2010.PubMed/NCBI View Article : Google Scholar
61	Bailey JR, Aggarwal A and Imperiale TF: Colorectal cancer screening: Stool DNA and other noninvasive modalities. Gut Liver. 10:204–211. 2016.PubMed/NCBI View Article : Google Scholar
62	Youssef O, Sarhadi V, Ehsan H, Böhling T, Carpelan-Holmström M, Koskensalo S, Puolakkainen P, Kokkola A and Knuutila S: Gene mutations in stool from gastric and colorectal neoplasia patients by next-generation sequencing. World J Gastroenterol. 23:8291–8299. 2017.PubMed/NCBI View Article : Google Scholar
63	Januszewicz W and Fitzgerald RC: Early detection and therapeutics. Mol Oncol. 13:599–613. 2019.PubMed/NCBI View Article : Google Scholar
64	Pickhardt PJ: Emerging stool-based and blood-based non-invasive DNA tests for colorectal cancer screening: The importance of cancer prevention in addition to cancer detection. Abdom Radiol (NY). 41:1441–1444. 2016.PubMed/NCBI View Article : Google Scholar
65	Shin HY, Suh M, Choi KS, Hwang SH, Jun JK, Han DS, Lee YK, Oh JH, Lee CW and Lee DH: Higher satisfaction with an alternative collection device for stool sampling in colorectal cancer screening with fecal immunochemical test: A cross-sectional study. BMC Cancer. 18(365)2018.PubMed/NCBI View Article : Google Scholar
66	de Wit M, Fijneman RJ, Verheul HM, Meijer GA and Jimenez CR: Proteomics in colorectal cancer translational research: Biomarker discovery for clinical applications. Clin Biochem. 46:466–479. 2013.PubMed/NCBI View Article : Google Scholar
67	Montrose DC, Zhou XK, Kopelovich L, Yantiss RK, Karoly ED, Subbaramaiah K and Dannenberg AJ: Metabolic profiling, a noninvasive approach for the detection of experimental colorectal neoplasia. Cancer Prev Res (Phila). 5:1358–1367. 2012.PubMed/NCBI View Article : Google Scholar
68	Slaby O: Non-coding RNAs as biomarkers for colorectal cancer screening and early detection. Adv Exp Med Biol. 937:153–170. 2016.PubMed/NCBI View Article : Google Scholar
69	Tsai TJ, Lim YP, Chao WY, Chen CC, Chen YJ, Lin CY and Lee YR: Capping actin protein overexpression in human colorectal carcinoma and its contributed tumor migration. Anal Cell Pathol (Amst). 2018(8623937)2018.PubMed/NCBI View Article : Google Scholar
70	Pan F, Chen T, Sun X, Li K, Jiang X, Försti A, Zhu Y and Lai M: Prognosis prediction of colorectal cancer using gene expression profiles. Front Oncol. 9(252)2019.PubMed/NCBI View Article : Google Scholar
71	Xu G, Zhang M, Zhu H and Xu J: A 15-gene signature for prediction of colon cancer recurrence and prognosis based on SVM. Gene. 604:33–40. 2017.PubMed/NCBI View Article : Google Scholar
72	Eckmann JD, Ebner DW and Kisiel JB: Multi-target stool DNA testing for colorectal cancer screening: Emerging learning on real-world performance. Curr Treat Options Gastroenterol: Jan 21, 2020 (Epub ahead of print).
73	Kisiel JB, Klepp P, Allawi HT, Taylor WR, Giakoumopoulos M, Sander T, Yab TC, Moum BA, Lidgard GP, Brackmann S, et al: Analysis of DNA methylation at specific loci in stool samples detects colorectal cancer and high-grade dysplasia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 17:914–921.e5. 2019.PubMed/NCBI View Article : Google Scholar
74	Naber SK, Knudsen AB, Zauber AG, Rutter CM, Fischer SE, Pabiniak CJ, Soto B, Kuntz KM and Lansdorp-Vogelaar I: Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of medicare beneficiaries. PLoS One. 14(e0220234)2019.PubMed/NCBI View Article : Google Scholar
75	Jung G, Hernández-Illán E, Moreira L, Balaguer F and Goel A: Epigenetics of colorectal cancer: Biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 17:111–130. 2020.PubMed/NCBI View Article : Google Scholar
76	Olén O, Erichsen R, Sachs MC, Pedersen L, Halfvarson J, Askling J, Ekbom A, Sørensen HT and Ludvigsson JF: Colorectal cancer in ulcerative colitis: A Scandinavian population-based cohort study. Lancet. 395:123–131. 2020.PubMed/NCBI View Article : Google Scholar
77	Chang CC, Chao KC, Huang CJ, Hung CS and Wang YC: Association between aberrant dynein cytoplasmic 1 light intermediate chain 1 expression levels, mucins and chemosensitivity in colorectal cancer. Mol Med Rep. 22:185–192. 2020.PubMed/NCBI View Article : Google Scholar
78	Hodge CD, Ismail IH, Edwards RA, Hura GL, Xiao AT, Tainer JA, Hendzel MJ and Glover JN: RNF8 E3 ubiquitin ligase stimulates Ubc13 E2 conjugating activity that is essential for DNA double strand break signaling and BRCA1 tumor suppressor recruitment. J Biol Chem. 291:9396–9410. 2016.PubMed/NCBI View Article : Google Scholar
79	Wu Z, Neufeld H, Torlakovic E and Xiao W: Uev1A-Ubc13 promotes colorectal cancer metastasis through regulating CXCL1 expression via NF-кB activation. Oncotarget. 9:15952–15967. 2018.PubMed/NCBI View Article : Google Scholar
80	Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D, Sun Y, You MJ, Liu Y, Dean DC, et al: miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun. 5(5671)2014.PubMed/NCBI View Article : Google Scholar
81	Pulvino M, Liang Y, Oleksyn D, DeRan M, Van Pelt E, Shapiro J, Sanz I, Chen L and Zhao J: Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A. Blood. 120:1668–1677. 2012.PubMed/NCBI View Article : Google Scholar
82	Cheng J, Fan YH, Xu X, Zhang H, Dou J, Tang Y, Zhong X, Rojas Y, Yu Y, Zhao Y, et al: A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. Cell Death Dis. 5(e1079)2014.PubMed/NCBI View Article : Google Scholar
83	Ishtiaq A, Bakhtiar A, Silas E, Saeed J, Ajmal S, Mushtaq I, Ali T, Wahedi HM, Khan W, Khan U, et al: Pistacia integerrima alleviated Bisphenol A induced toxicity through Ubc13/p53 signalling. Mol Biol Rep. 47:6545–6559. 2020.PubMed/NCBI View Article : Google Scholar
84	Pelletier J, Riaño-Canalias F, Almacellas E, Mauvezin C, Samino S, Feu S, Menoyo S, Domostegui A, Garcia-Cajide M, Salazar R, et al: Nucleotide depletion reveals the impaired ribosome biogenesis checkpoint as a barrier against DNA damage. EMBO J. 39(e103838)2020.PubMed/NCBI View Article : Google Scholar
85	Ouchida M, Kanzaki H, Ito S, Hanafusa H, Jitsumori Y, Tamaru S and Shimizu K: Novel direct targets of miR-19a identified in breast cancer cells by a quantitative proteomic approach. PLoS One. 7(e44095)2012.PubMed/NCBI View Article : Google Scholar
86	Zhao G, Liu X, Liu Y, Li H, Ma Y, Li S, Zhu Y, Miao J, Xiong S, Fei S and Zheng M: Aberrant DNA methylation of SEPT9 and SDC2 in stool specimens as an integrated biomarker for colorectal cancer early detection. Front Genet. 11(643)2020.PubMed/NCBI View Article : Google Scholar
87	Gu Y, Lin X, Kapoor A, Chow MJ, Jiang Y, Zhao K and Tang D: The oncogenic potential of the centromeric border protein FAM84B of the 8q24.21 gene desert. Genes (Basel). 11(312)2020.PubMed/NCBI View Article : Google Scholar
88	Uyama T, Jin XH, Tsuboi K, Tonai T and Ueda N: Characterization of the human tumor suppressors TIG3 and HRASLS2 as phospholipid-metabolizing enzymes. Biochim Biophys Acta. 1791:1114–1124. 2009.PubMed/NCBI View Article : Google Scholar
89	Shyu RY, Hsieh YC, Tsai FM, Wu CC and Jiang SY: Cloning and functional characterization of the HRASLS2 gene. Amino Acids. 35:129–137. 2008.PubMed/NCBI View Article : Google Scholar
90	Bi F, Wang Q, Dong Q, Wang Y, Zhang L and Zhang J: Circulating tumor DNA in colorectal cancer: Opportunities and challenges. Am J Transl Res. 12:1044–1055. 2020.PubMed/NCBI
91	Lansdorp-Vogelaar I, Goede SL, Bosch LJW, Melotte V, Carvalho B, van Engeland M, Meijer GA, de Koning HJ and van Ballegooijen M: Cost-effectiveness of high-performance biomarker tests vs fecal immunochemical test for noninvasive colorectal cancer screening. Clin Gastroenterol Hepatol. 16:504–512.e11. 2018.PubMed/NCBI View Article : Google Scholar